MaxRex

MaxRex emerged from a strategic acquisition that brought together Chinese healthcare commercialization capabilities with pioneering exoskeleton technology from New Zealand. In January 2020, iMax Health (美安医药), a Wuxi-based medical technology platform, acquired Rex Bionics—one of the first companies globally to commercialize rehabilitation exoskeletons—and restructured it as Wuxi MaxRex Medical Robot Co., Ltd. to serve the Chinese and global markets.

Company Overview

The acquisition positioned MaxRex as the global R&D, manufacturing, and commercial operations hub for Rex technology, while maintaining overseas research and service centers. iMax Health, established in 2009, operates from multiple locations including Shanghai, Beijing, Hong Kong, London, and Tokyo, providing MaxRex with established healthcare distribution channels and regulatory expertise.

CEO Miao Fengdong has articulated the company’s mission as developing “hard technology” solutions for rehabilitation medicine, particularly in neurological rehabilitation. The company’s technology portfolio extends beyond exoskeletons to include rehabilitation laser products and AI-powered rehabilitation tools, all targeting fundamental clinical pain points in the rehabilitation process.

Core Products

REX Self-Balancing Exoskeleton

The flagship REX system represents a distinctive approach to lower-limb rehabilitation robotics. Unlike most rehabilitation exoskeletons that require overhead suspension systems, walking frames, or crutches for patient support, the REX achieves self-balancing through integrated mechanical systems and intelligent algorithms. This design frees patients’ upper limbs during rehabilitation sessions, enabling them to perform complex physical therapy exercises while standing.

The system received both FDA clearance and CE Mark certification in 2016, placing Rex Bionics among the first generation of commercially approved rehabilitation exoskeletons globally. Since MaxRex assumed operations, the system has also obtained NMPA certification for the Chinese market.

Clinical applications focus on patients with neurological conditions including spinal cord injuries, stroke, traumatic brain injuries, and multiple sclerosis. The exoskeleton provides multi-degree-of-freedom movement with customizable rehabilitation protocols, supporting early intervention during the acute rehabilitation phase.

Research collaborations with universities domestically and internationally have explored brain-computer interface integration, successfully demonstrating that patients with high-level spinal cord injuries can control walking functions through neural signals.

Technology & Innovation

The REX platform’s core differentiator lies in its self-balancing capability. Conventional rehabilitation exoskeletons typically require external support structures because the combined weight and movement of the device and patient creates instability. MaxRex’s approach employs biomechanical engineering principles combined with real-time balance algorithms to maintain stability without external aids.

The exoskeleton uses ergonomic design principles that align robotic joint movements with natural human movement patterns, optimizing both therapeutic effectiveness and user comfort. Each joint features independent drive mechanisms, ensuring that the robot’s degrees of freedom remain coaxial with the patient’s natural joint axes.

Pipeline Development

MaxRex has announced development programs for several complementary rehabilitation technologies: a bedside rehabilitation robot for patients unable to stand, an ambulatory rehabilitation robot to assist patient walking, and a laser rehabilitation therapy device targeting soft tissue injuries. The company also continues work on brain-computer interface applications for the existing exoskeleton platform.

Market Presence

The company targets both institutional and individual markets. For rehabilitation facilities, MaxRex offers both purchase and rental models, with the rental option enabling hospitals to add capabilities without significant capital expenditure. According to company estimates, facilities purchasing the system can achieve return on investment within approximately one year.

MaxRex emphasizes the health economics value proposition of effective rehabilitation, noting that full rehabilitation can enable 90% of stroke patients to recover walking ability and independence in daily activities, compared to only 6% without rehabilitation intervention. This significant outcome difference supports the case for rehabilitation technology investment.

Key Milestones

• 2016: Rex Bionics REX exoskeleton receives FDA and CE certification
• 2020: iMax Health acquires Rex Bionics, establishes MaxRex as Chinese operating entity
• 2022: Company announces plans for ¥80 million financing round
• Post-2022: NMPA certification obtained for Chinese market

Frequently Asked Questions

What makes the REX exoskeleton different from other rehabilitation robots?

The REX is distinguished by its self-balancing capability. While most rehabilitation exoskeletons require overhead suspension systems, walking frames, or crutches for patient support, the REX maintains stability independently through integrated mechanical systems and intelligent algorithms. This allows patients to use their hands freely during rehabilitation sessions.

Who can benefit from REX rehabilitation?

The system primarily serves patients with neurological conditions affecting lower-limb function, including spinal cord injuries at various levels, stroke-related paralysis, traumatic brain injuries, and multiple sclerosis. The self-balancing feature makes it particularly suitable for patients with severe impairments who cannot use crutches or provide upper-body support.

Is the REX exoskeleton approved for use in China?

Yes, the REX system has obtained NMPA certification for the Chinese market in addition to its earlier FDA clearance and CE Mark certification, enabling commercial use in hospitals and rehabilitation centers across China.